Tom Johnson
LifeSite Advisors
Replay available
PDS Biotechnology Corporation (PDSB) Q3 2025 Earnings Call
PDS Biotechnology Corporation (NASDAQ: PDSB) Q3 2025 earnings conference call, held 2025-11-13. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Mayank Marutani
Analyst, B. Riley Securities
Dr. Frank Beto-Addo
Chief Executive Officer
Joe Penginnis
Analyst, HC Wainwright
Dr. Kirk Shepherd
Chief Medical Officer
Lars Bozgaard
Chief Financial Officer
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Pds Biotechnology Corporation.
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.218 Greetings. Welcome to the PDS Biotech's third quarter 2025 earnings conference call. 00:00:05.218 -- 00:00:08.143 At this time, all participants are in listen-only mode. 00:00:08.143 -- 00:00:12.168 The question and answer session will follow the formal presentation. 00:00:12.168 -- 00:00:15.914 If anyone should require operator assistance during the conference, please press star 00:00:15.914 -- 00:00:21.482 zero on your telephone keypad. Please note that this conference is being recorded. 00:00:21.482 -- 00:00:25.708 At this time, we'll turn the conference over to Tom Johnson with LifeSite Advisors. 00:00:25.708 -- 00:00:28.349 Tom, you may now begin. 00:00:28.482 -- 00:00:32.646 Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's third quarter 00:00:32.646 -- 00:00:36.550 2025 results and clinical programs update call. 00:00:36.550 -- 00:00:39.994 I'm joined on the call today by the following members of the company's management team, 00:00:39.994 -- 00:00:43.938 Dr. Frank Beto-Addo, Chief Executive Officer, Dr. 00:00:43.938 -- 00:00:49.263 Kirk Shepherd, Chief Medical Officer, and Lars Bozgaard, Chief Financial Officer. 00:00:49.263 -- 00:00:53.227 Dr. Beto-Addo will begin with an overview of the company's recent progress and its clinical 00:00:53.227 -- 00:00:57.616 development program. Mr. Boesgaard will review the financial results for the quarter 00:00:57.616 -- 00:01:03.004 ended September 30, 2025, and Dr. Shepard will then join the call to help address questions 00:01:03.004 -- 00:01:05.327 from covering analysts. 00:01:05.327 -- 00:01:09.093 As a reminder, during this call, we will make forward-looking statements, which are subject 00:01:09.093 -- 00:01:13.280 to various risks and uncertainties that ...